Welcome to our dedicated page for Medicinova news (Ticker: MNOV), a resource for investors and traders seeking the latest updates and insights on Medicinova stock.
MediciNova, Inc. (MNOV) generates frequent news as a clinical-stage biopharmaceutical company advancing late-stage small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Company announcements emphasize progress in its two core programs, MN-166 (ibudilast) and MN-001 (tipelukast), across multiple serious conditions.
News updates commonly cover clinical trial milestones, such as completion of patient enrollment, trial design details, and presentations at major scientific meetings. Examples include the COMBAT-ALS Phase 2b/3 trial of MN-166 in amyotrophic lateral sclerosis, the OXTOX study in chemotherapy-induced peripheral neuropathy, and the MN‑001‑NATG‑202 Phase 2 trial in hypertriglyceridemia and non-alcoholic fatty liver disease due to type 2 diabetes.
Investors and observers can also expect scientific and mechanistic updates, including peer-reviewed publications on MN-001 and its metabolite MN-002 in cholesterol and lipid metabolism, as well as letters from the CEO explaining how new data support the company’s development strategy. Regulatory and advisory appointments, such as the addition of experienced clinical and regulatory advisors, are another regular theme in MediciNova’s news flow.
Because MediciNova is listed on Nasdaq and the Tokyo Stock Exchange, its news often includes capital markets and investor relations events, such as conference presentations and corporate overviews for institutional and individual investors. This news page aggregates these developments so readers can follow clinical progress, scientific publications, regulatory interactions, and corporate updates related to MNOV in one place.
MediciNova (NASDAQ:MNOV) announced that as of January 2026, 100 patients have been enrolled in the NIH‑funded SEANOBI Expanded‑Access Program (EAP) evaluating MN‑166 (ibudilast) in ALS, representing 50% of the planned 200 enrollment across 12 activated US sites. The program is supported by a $22 million NINDS grant under ACT for ALS and will generate real‑world biomarker and clinical outcome data alongside the COMBAT‑ALS Phase 2b/3 randomized trial (234 patients enrolled; topline expected by end of 2026).
MediciNova (NASDAQ:MNOV) CEO Yuichi Iwaki delivered a New Year letter on Jan 6, 2026 outlining 2025 clinical progress and 2026 priorities.
Clinical highlights: enrollment completed in three trials—COMBAT‑ALS (MN‑166) completed enrollment Sept 2025 with top‑line results expected by year‑end; OXTOX Phase 2b completed enrollment Dec 2025; MN‑001 Phase 2 enrollment completed Nov 2025 with top‑line data anticipated summer 2026. An Expanded Access Program for ALS launched March 2025 supported by a $22 million NIH grant; as of Dec 15, 2025 there were 12 U.S. sites and 87 patients enrolled.
The company says 2026 will be pivotal as it prepares for potential regulatory submission if COMBAT‑ALS results are positive.
MediciNova (NASDAQ:MNOV) announced completion of patient enrollment in the randomized, placebo-controlled Phase 2 OXTOX study evaluating MN-166 (ibudilast) to prevent chemotherapy-induced peripheral neuropathy in metastatic colorectal cancer.
A total of 100 patients were randomized across two arms at 11 clinical sites in Australia. Patient recruitment is closed; participants continue chemotherapy with assigned study drug until disease progression or unacceptable toxicity. The study will conclude when the final patient reaches six months post-chemotherapy. Top-line data are anticipated later in 2026, though no exact completion date is provided.
MediciNova (NASDAQ:MNOV) reported an update from the COMBAT-ALS Phase 2b/3 trial of MN-166 (ibudilast) presented at the 36th International Symposium on ALS/MND (Dec 5–7, 2025).
Key facts: 234 participants randomized, enrollment completed Sept 2025. Baseline metrics: mean age 60.6, mean ALSFRS-R 40.6, mean disease duration 12.5 months. Sex split: 36.8% female, 63.2% male. Racial mix: Caucasian 90.2%, Asian 5.1%.
The company noted COVID-19–related enrollment challenges, is offering continued access via FDA individual expanded access, and cited FDA Orphan Drug and Fast Track designations and European orphan designation. Top-line data are anticipated by end of 2026.
MediciNova (MNOV) reported a peer-reviewed publication showing MN-002, the primary metabolite of MN-001, increases cholesterol efflux by upregulating ABCA1 and ABCG1 in macrophages, a mechanism tied to Reverse Cholesterol Transport.
The company completed patient enrollment in its Phase 2 MN-001-NATG-202 randomized, double-blind, placebo-controlled trial in hypertriglyceridemia and NAFLD due to T2DM; top-line results are expected by summer 2026. Management says the mechanistic data reinforce prior clinical lipid-profile observations and will inform next steps toward advancing MN-001 as a potential first-in-class therapy for metabolic and cardiovascular disease.
MediciNova (NASDAQ:MNOV) announced on November 18, 2025 the appointment of Dr. Christopher D. Breder, MD, PhD as Clinical and Regulatory Advisor. Dr. Breder will provide strategic guidance for MediciNova’s drug development programs and will lead the Scientific Advisory Board upon its formation.
Dr. Breder brings over two decades of regulatory and clinical experience, including more than a decade at the FDA as Medical Officer and Lead Medical Officer, involvement in NDA review and safety analysis training, and participation in reviews and initial approvals for therapies targeting ALS, myasthenia gravis, and Duchenne muscular dystrophy. He holds an MD and PhD from the University of Chicago and completed clinical training at Johns Hopkins Hospital.
MediciNova (NASDAQ:MNOV) announced on November 6, 2025 that it won the Contract Research and Development Innovation Award at the Fifth Annual BioTech Breakthrough Awards.
The award recognizes MediciNova's work advancing MN-166 (ibudilast), its lead small-molecule candidate in development for multiple neurological diseases including ALS. The company noted ongoing progress in the Phase 2/3 COMBAT-ALS trial and said the recognition highlights its focus on neuroinflammation modulation and neuroprotection as a potential disease-modifying approach.
MediciNova (NASDAQ:MNOV) announced completion of patient enrollment in the Phase 2 MN-001-NATG-202 trial of MN-001 (tipelukast) for hypertriglyceridemia and NAFLD due to Type 2 diabetes.
The multi-center, randomized, double-blind, placebo-controlled study randomizes patients 1:1 to 500 mg/day MN-001 or placebo for 24 weeks. Co-primary endpoints are change in liver fat by CAP score and change in fasting serum triglycerides at Week 24. Secondary endpoints include safety, tolerability, and changes in HDL-C, LDL-C, and total cholesterol. Patient recruitment is closed and top-line data are expected by summer 2026.
MediciNova (NASDAQ:MNOV) announced a peer-reviewed study published Oct 30, 2025 showing that MN-002, the primary metabolite of investigational tipelukast (MN-001), enhanced cholesterol efflux in macrophages by upregulating transport proteins ABCA1 and ABCG1. The research, conducted with a Japanese academic group and published in the Journal of Atherosclerosis and Thrombosis, suggests a novel mechanism of action and a potential therapeutic strategy for atherosclerosis and metabolic disorders.
MediciNova said MN-001 is an oral small molecule with anti-inflammatory and anti-fibrotic properties, prior clinical studies showed improved serum lipid profiles in NAFLD and hypertriglyceridemia patients, and a randomized double-blind Phase 2 study in hypertriglyceridemia, type 2 diabetes, and NAFLD is nearing enrollment completion.
MediciNova (NASDAQ: MNOV) will present a corporate overview at the LD Micro Main Event XIX in San Diego on Monday, October 20, 2025 at 1:30 PM PT. Presenters are Yuichi Iwaki, M.D., Ph.D., President and CEO, and David H. Crean, Ph.D., Chief Business Officer.
A live webcast will be available via the company's investor relations website and a replay will be archived for 90 days. The presenters will be available for one-on-one meetings during the conference (October 19–22, 2025).
FAQ
What is the current stock price of Medicinova (MNOV)?
What is the market cap of Medicinova (MNOV)?
